Selective sensitization to DNA-damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 overexpression

Clinical Cancer Research

Volumn 4, Issue 1, 1998, Pages 145-152

  Gibson, Alice A ^a   Harwood, Franklin G ^a   Tillman, David M ^a   Houghton, Janet A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORAMPHENICOL ACETYLTRANSFERASE; CISPLATIN; COMPLEMENTARY DNA; CYTOTOXIC AGENT; DACTINOMYCIN; DEXAMETHASONE; DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HYBRID PROTEIN; MUTANT PROTEIN; PROTEIN P21; PROTEIN P53; TOPOTECAN; VINCRISTINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG MECHANISM; DRUG SENSITIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPORTER GENE; RHABDOMYOSARCOMA; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; DNA; DNA DAMAGE; DNA-BINDING PROTEINS; HUMANS; PAIRED BOX TRANSCRIPTION FACTORS; RHABDOMYOSARCOMA; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031930518     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Livingstone, L. R., White, A., Spouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
2. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. Wild-type p53 restores cell-cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
3. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (Lond.), 356: 215-221, 1992.
4. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4: 1-7, 1994.
5. Lane, D. P. p53, guardian of the genome. Nature (Lond.), 358: 15-16, 1992.
6. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
7. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
8. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. P., Parsons, R., Trent, J. M., Liu, D., Merrer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
9. Dulic, V., Kaufmann, W. K., Wilson, S. J., Tlsty, T. D., Lees, E., Harper, J. W., Elledge, S. J., and Reed, S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76: 1013-1023, 1994.
10. Gartenhaus, R. B., Wang, P., and Hoffmann, P. Induction of the WAF1/C1P1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc. Natl. Acad. Sci. USA, 93: 265-268, 1996.
11. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res., 56: 4430-4437, 1996.
12. Nutt, C. L., Chambers, A. F., and Cairncross, J. G. Wild-type p53 renders mouse astrocytes resistant to 1,3-bis(2-chloroethyl)-1-nitro-sourea despite the absence of a p53-dependent cell cycle arrest. Cancer Res., 56: 2748-2751, 1996.
13. 2 checkpoint in p53-independent apoptosis induction by X-irradiation. Mol. Cell. Biol., 15: 5849-5857, 1995.
14. Dou, Q-P., An, B., and Will, P. L. Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc. Natl. Acad. Sci. USA, 92: 9019-9023, 1995.
15. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4: 1-7, 1994.
16. Mulligan, L. M., Matlashewski, G. J., Scrable, H. J., and Cavenee, W. K. Mechanisms of p53 loss in human sarcomas. Proc. Natl. Acad. Sci. USA, 87: 5863-5867, 1990.
17. Douglass, E. C., Valentine, M., Etcubanas, E., Parham, D., Webber, B. L., Houghton, J. A., Houghton, P. J., and Green, A. A. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet. Cell Genet., 45: 148-155, 1987.
18. Dicker, A. P., Volkenandt, M., and Albino, A. P. Mutational analysis of human N-Ras genes in malignant melanoma: rapid methods for oligonucleotide hybridization and manual and automated direct sequencing of products generated by the polymerase chain reaction. Genes Chromosomes Cancer, 1: 257-269, 1990.
19. Manam, S., and Nichols, W. W. Multiplex polymerase chain reaction amplification and direct-sequencing of homologous sequences: point mutation analysis of the Ras genes. Anal. Biochem., 199: 106-111, 1991.
20. Felix, C. A., Kappel, C. C., Mitsudomi, T., Nau, M. M., Tsokos, M., Crouch, G. D., Nisen, P. D., Winick, P. J., and Helman, L. J. Frequency and diversity of p53 mutations in childhood rhabdomyosarcomas. Cancer Res., 52: 2243-2247, 1992.
21. Mader, S., and White, J. A steroid-inducible promoter for the controlled overexpression of cloned genes in eukaryotic cells. Proc. Natl. Acad. Sci. USA, 90: 5603-5607, 1993.
22. Houghton, J. A., Harwood, F. G., and Houghton, P. J. Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. Cancer Res., 54: 4967-4973, 1994.
23. Harwood, F. G., Frazier, M. W., Krajewski, S., Reed, J. C., and Houghton, J. A. Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells. Oncogene, 12: 2057-2067, 1996.
24. Lowe, S. W., Ruley, H. E., Jacks, T., and Housemann, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell, 74: 957-967, 1993.
25. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
26. Benveniste, P., and Cohen, A. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc. Natl. Acad. Sci. USA, 92: 8373-8377, 1995.
27. Gjerset, R. A., Turla, S. T., Scalise, J. J., Sobol, R. E., Shawler, D. L., and Hopkins, P. J. Dominant effect of transduced wild-type p53 over endogenous mutant p53 in sensitizing tumor cells to therapy. Proc. Am. Assoc. Cancer Res., 36A: A123, 1995.
28. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen-Schaub, W. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
29. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Blatia, K., Fornace, A. J., Magrath, I., Kohn, K. W., and O'Connor, P. M.p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
30. Labrecque, S., and Matlashewski, G. J. Viability of wild type p53-containing and p53 deficient tumor cells following anticancer treatment. The use of human papilloma virus E6 to target p53. Oncogene, 11: 387-392, 1995.
31. Slichenmeyer, W. J., Nelson, W. G., Slebos, R. J., and Kastan, M. B. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
32. Fan, S., Smith, M. L., River, D. J., II, Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
33. Packham, G., and Cleveland, J. L. c-Myc and apoptosis. Biochim. Biophys. Acta, 1242: 11-28, 1995.
34. Yang, B., Eshleman, J. R., Berger, N. A., and Markowitz, S. D. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon carcinoma cells. Clin. Cancer Res., 2: 1649-1657, 1996.
35. Spencer, C. A., and Groudine, M. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res., 56: 1-48, 1991.
36. Lotem, J., and Sachs, L. Regulation of bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation competent and defective myeloid leukemia cells. Cell Growth Differ., 4: 41-47, 1993.
37. Arends, M. J., McGregor, A. H., Toft, N. J., Brown, E. J., and Wyllie, A. H. Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br. J. Cancer, 68: 1127-1133, 1993.
38. Chen, C. H., Zhang, J., and Ling, C. C. Transfected c-myc and c-Ha-ras modulate radiation-induced apoptosis in rat embryo cells. Radiat. Res., 139: 307-315, 1994.
39. Basu, A., and Cline, J. S. Oncogenic transformation alters cisplatin-induced apoptosis. Proc. Am. Assoc. Cancer Res., 36: A17, 1995.
40. Driman, D., Thorner, P. S., Greenberg, M. C., Chilton-Macneill, S., and Squire, J. MCYN gene amplification in rhabdomyosarcoma. Cancer (Phila.), 73: 2231-2237, 1994.
41. Dias, P., Kumar, P., Marsden, H. B., Gattamaneni, H. R., Heighway, J., and Kumar, S. N-Myc gene is amplified in alveolar rhabdomyosarcoma (RMS) but not in embryonal RMS. Int. J. Cancer, 45: 593-596, 1990.